Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PDSB 
PDS Biotechnology Corp (PDSB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PDSB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -75.34% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 54.85M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 3 | Beta 0.94 | 52 Weeks Range 0.85 - 4.29 | Updated Date 08/15/2025 |
52 Weeks Range 0.85 - 4.29 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.91 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.22 | Actual -0.21 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.06% | Return on Equity (TTM) -119.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 41515271 | Price to Sales(TTM) - |
Enterprise Value 41515271 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.58 | Shares Outstanding 45710000 | Shares Floating 39605610 |
Shares Outstanding 45710000 | Shares Floating 39605610 | ||
Percent Insiders 3.09 | Percent Institutions 19.57 |
Upturn AI SWOT
PDS Biotechnology Corp
Company Overview
History and Background
PDS Biotechnology Corp. is a clinical-stage biopharmaceutical company focused on developing immunotherapies to treat cancer and infectious diseases. Founded in 2006, the company's initial focus was on developing a platform technology to enhance the immune response to vaccines. Over time, it has shifted its focus to developing immunotherapies for cancer.
Core Business Areas
- Versamuneu00ae Platform: PDS Biotech's core technology platform. It's designed to deliver antigens directly to antigen-presenting cells (APCs) to elicit a potent T-cell immune response.
- PDS0101: A Versamuneu00ae-based immunotherapy targeting HPV16-associated cancers. Currently in clinical trials for various HPV-related cancers.
- PDS0301: A Versamuneu00ae-based immunotherapy being developed for treating advanced solid tumors
Leadership and Structure
Dr. Frank Bedu-Addo is the President and CEO. The company has a board of directors and a management team overseeing research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- PDS0101: A lead product candidate targeting HPV16-associated cancers. Currently in Phase 2 clinical trials. No market share yet as it is pre-commercial. Competitors include companies developing similar HPV-targeted therapies like Merck (Keytruda + chemotherapy in some settings) and other companies focusing on cancer vaccines or T-cell therapies.
- Versamuneu00ae Platform: The proprietary platform used to develop PDS0101. Not directly sold, but underpins the company's pipeline. No direct market share as it's a technology platform. However it does create value, through the products that use the technology
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, with significant investment and innovation in cancer vaccines and T-cell therapies.
Positioning
PDS Biotechnology Corp is focused on developing novel immunotherapies using its Versamuneu00ae platform, aiming to provide improved efficacy and safety compared to existing treatments.
Total Addressable Market (TAM)
The global cancer immunotherapy market is projected to reach hundreds of billions of dollars in the coming years. PDS Biotech's positioning, focusing on HPV-associated cancers, aims to capture a portion of this growing market.
Upturn SWOT Analysis
Strengths
- Proprietary Versamuneu00ae platform technology
- Targeted approach to cancer immunotherapy (HPV16)
- Promising early clinical trial data
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources as a clinical-stage company
- High risk associated with drug development
- Reliance on a single platform technology
- No currently marketed products (pre-revenue)
Opportunities
- Expansion of the Versamuneu00ae platform to other cancer targets
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to accelerated approval
- Expanding addressable cancer types with new applications of Versamune
Threats
- Competition from established immunotherapy companies
- Failure of clinical trials
- Regulatory hurdles and delays
- Economic downturn impacting investment in biotech
Competitors and Market Share
Key Competitors
- MRK
- BMY
- GILD
- NVS
- PFE
Competitive Landscape
PDS Biotech's competitive advantage lies in its Versamuneu00ae platform. However, it faces significant competition from larger, more established companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by expansion of the clinical pipeline and financing activities.
Future Projections: Future growth is contingent upon positive clinical trial results and regulatory approvals for PDS0101 and other pipeline candidates. Analyst estimates vary widely based on the perceived probability of success.
Recent Initiatives: Recent initiatives include enrollment in ongoing clinical trials, presentations at scientific conferences, and potential partnerships.
Summary
PDS Biotechnology is a clinical-stage company developing immunotherapies, particularly PDS0101 for HPV-associated cancers. Its Versamuneu00ae platform holds promise, but the company faces financial constraints and competition from larger players. Positive clinical trial results are crucial for its success. Investment into research and development should be a priority in order to get the product into the market. Clinical trial failure should be looked out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share numbers are estimates based on general competitor data, since PDSB currently doesn't have a product on the market.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PDS Biotechnology Corp
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2015-10-01 | President, CEO & Director Dr. Frank K. Bedu-Addo Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.pdsbiotech.com |
Full time employees 24 | Website https://www.pdsbiotech.com | ||
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.